Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies

NCT02915172 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT02915172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02915172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Withdrawn
Start date
December 31, 2016
Completion date
Not reported
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, malignant neoplasm of breast, malignant neoplasms of bone and articular cartilage, malignant neoplasms of digestive organs, malignant neoplasms of eye brain and other parts of central nervous system, malignant neoplasms of female genital organs, malignant neoplasms of ill-defined secondary and unspecified sites, malignant neoplasms of independent (primary) multiple sites, malignant neoplasms of lip oral cavity and pharynx, malignant neoplasms of male genital organs, malignant neoplasms of mesothelial and soft tissue, malignant neoplasms of respiratory and intrathoracic organs, malignant neoplasms of thyroid and other endocrine glands, malignant neoplasms of urinary tract